These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34725436)

  • 21. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency.
    Shen X; Liu Y; Hsu YJ; Fujiwara Y; Kim J; Mao X; Yuan GC; Orkin SH
    Mol Cell; 2008 Nov; 32(4):491-502. PubMed ID: 19026780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CLDN14 is epigenetically silenced by EZH2-mediated H3K27ME3 and is a novel prognostic biomarker in hepatocellular carcinoma.
    Li CP; Cai MY; Jiang LJ; Mai SJ; Chen JW; Wang FW; Liao YJ; Chen WH; Jin XH; Pei XQ; Guan XY; Zeng MS; Xie D
    Carcinogenesis; 2016 Jun; 37(6):557-566. PubMed ID: 27207647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
    Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
    J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EZH2: a novel target for cancer treatment.
    Duan R; Du W; Guo W
    J Hematol Oncol; 2020 Jul; 13(1):104. PubMed ID: 32723346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons.
    Henriquez B; Bustos FJ; Aguilar R; Becerra A; Simon F; Montecino M; van Zundert B
    Mol Cell Neurosci; 2013 Nov; 57():130-43. PubMed ID: 23932971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long non-coding RNA FOXP4-AS1 facilitates the biological functions of hepatocellular carcinoma cells via downregulating ZC3H12D by mediating H3K27me3 through recruitment of EZH2.
    Ye J; Fu Y; Wang Z; Yu J
    Cell Biol Toxicol; 2022 Dec; 38(6):1047-1062. PubMed ID: 34545456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Six Years (2012-2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2-Pyridone Compounds.
    Fioravanti R; Stazi G; Zwergel C; Valente S; Mai A
    Chem Rec; 2018 Dec; 18(12):1818-1832. PubMed ID: 30338896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.
    Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM
    Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-20a Suppresses Tumor Proliferation and Metastasis in Hepatocellular Carcinoma by Directly Targeting EZH1.
    Zhang Q; Deng X; Tang X; You Y; Mei M; Liu D; Gui L; Cai Y; Xin X; He X; Huang J
    Front Oncol; 2021; 11():737986. PubMed ID: 34976797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
    Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
    EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maternal Ezh1/2 deficiency in oocyte delays H3K27me2/3 restoration and impairs epiblast development responsible for embryonic sub-lethality in mouse.
    Zhao Y; Bai D; Wu Y; Zhang D; Liu M; Tian Y; Lu J; Wang H; Gao S; Lu Z
    Development; 2022 Aug; 149(15):. PubMed ID: 35796552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
    Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
    Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
    Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
    Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The competitive mechanism of EZH1 and EZH2 in promoting oral squamous cell carcinoma.
    Chen J; Tang S; Zheng Q; Li J; Jiang H; Lu H; Liao G; Li K; Liang Y
    Exp Cell Res; 2024 Mar; 436(1):113957. PubMed ID: 38309675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis.
    Lee YY; Mok MT; Kang W; Yang W; Tang W; Wu F; Xu L; Yan M; Yu Z; Lee SD; Tong JHM; Cheung YS; Lai PBS; Yu DY; Wang Q; Wong GLH; Chan AM; Yip KY; To KF; Cheng ASL
    Nucleic Acids Res; 2018 Sep; 46(17):8832-8847. PubMed ID: 29992318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The methyltransferases enhancer of zeste homolog (EZH) 1 and EZH2 control hepatocyte homeostasis and regeneration.
    Bae WK; Kang K; Yu JH; Yoo KH; Factor VM; Kaji K; Matter M; Thorgeirsson S; Hennighausen L
    FASEB J; 2015 May; 29(5):1653-62. PubMed ID: 25477280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
    McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
    Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
    Knutson SK; Wigle TJ; Warholic NM; Sneeringer CJ; Allain CJ; Klaus CR; Sacks JD; Raimondi A; Majer CR; Song J; Scott MP; Jin L; Smith JJ; Olhava EJ; Chesworth R; Moyer MP; Richon VM; Copeland RA; Keilhack H; Pollock RM; Kuntz KW
    Nat Chem Biol; 2012 Nov; 8(11):890-6. PubMed ID: 23023262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
    Yamagishi M; Hori M; Fujikawa D; Ohsugi T; Honma D; Adachi N; Katano H; Hishima T; Kobayashi S; Nakano K; Nakashima M; Iwanaga M; Utsunomiya A; Tanaka Y; Okada S; Tsukasaki K; Tobinai K; Araki K; Watanabe T; Uchimaru K
    Cell Rep; 2019 Nov; 29(8):2321-2337.e7. PubMed ID: 31747604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting EZH2 in cancer.
    Kim KH; Roberts CW
    Nat Med; 2016 Feb; 22(2):128-34. PubMed ID: 26845405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.